Eli Lilly’s Tirzepatide Shows Reduction in Risk of Heart Failure Outcomes
Phase III study of tirzepatide in adults with heart failure with preserved ejection fraction and obesity met all primary endpoints.
According to new data revealed by Eli Lilly, tirzepatide significantly improved heart failure symptoms and physical limitations in adults with heart failure with preserved ejection fraction (HFpEF) and obesity. Data emerged from the Phase III SUMMIT clinical trial, which met both of its primary endpoints as well as key secondary endpoints.1
Tirzepatide also improved exercise capacity, reduced the inflammation marker high-sensitivity C-reactive protein (hsCRP), and displayed a mean body weight reduction from baseline at 52 weeks. In a combined population of people with and without type 2 diabetes, tirzepatide led to 15.7% weight loss.
Heart failure is typically classified based on the contraction of the heart muscle or the filling of the heart chambers. When the heart muscle is too weak, the condition is known as HFpEF. A number of chronic medical conditions can cause this condition including obesity, high blood pressure, chronic obstructive pulmonary disease, and sleep apnea.2
In a press release, Jeff Emmick, MD, PhD, senior vice president, product development, Lilly said, “HFpEF accounts for nearly half of all heart failure cases, and in the U.S. almost 60% of those impacted also live with obesity. Despite a continuing increase in the number of people with both HFpEF and obesity, treatment options remain limited. Previous incretin studies in this population focused on symptoms and physical limitations. In a first-of-its-kind trial, tirzepatide reduced severity of symptoms and improved heart failure outcomes in people with HFpEF and obesity.”
The Phase III Summit trial (
Earlier in June, results from the Phase III SURMOUNT-OSA (
“Symptoms of [OSA] represent a substantial disease burden and increased risk of injury, including increased risk of motor vehicle accidents and work-related injuries,” the study authors wrote. “The symptom severity in [OSA] may also be a predictor of increased risk of cardiovascular complications. Therefore, it is clinically relevant that in the current trials, positive effects of tirzepatide on the participants’ sleep-related functioning and sleep disturbance were detected on the basis of PROMIS-SRI and PROMIS-SD scores.”
The FDA approved tirzepatide for chronic weight management in November 2023 based on Phase III results from the SURMOUNT-1 and SURMOUNT-2 trials.4
In an earlier press release, Leonard Glass, MD, FACE, senior vice president global medical affairs, Lilly Diabetes and Obesity said, “Unfortunately, despite scientific evidence to the contrary, obesity is often seen as a lifestyle choice—something that people should manage themselves. For decades, diet and exercise have been a go-to, but it's not uncommon for a person to have tried 20-30 times to lose weight with this approach. Research now shows that the body may respond to a calorie-deficit diet by increasing hunger and reducing feelings of fullness, making weight loss more difficult. Lilly is aiming to eliminate misperceptions about this disease and transform how it can be managed.”
References
1. Lilly's tirzepatide successful in phase 3 study showing benefit in adults with heart failure with preserved ejection fraction and obesity. News release. Eli Lilly. August 1, 2024. Accessed August 5, 2024.
2. Heart Failure with Preserved Ejection Fraction (HFpEF). Frankel Cardiovascular Center, University of Michigan Health. Accessed August 5, 2024.
3. Tirzepatide Produces Clinically Meaningful Improvement in Symptoms of Obstructive Sleep Apnea. Applied Clinical Trials. June 26, 2024. Accessed August 5, 2024.
4. FDA Approves Lilly's Zepbound™ (tirzepatide) for Chronic Weight Management, a Powerful New Option for the Treatment of Obesity or Overweight with Weight-Related Medical Problems. News release. Eli Lilly. November 8, 2023. Accessed August 5, 2024.
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Related Articles
- How the NIMBLE Study Supported Adherence With Quarterly Dosing of Cemdisiran
September 18th 2025
- Everything to Know About FDA’s Push Towards Radical Transparency in 2025
September 17th 2025
- IQVIA and Veeva Join Forces to Improve Efficiency and Patient Outcomes
September 17th 2025
- Managing Background Therapies in the NIMBLE Phase III Trial
September 17th 2025